Jeffrey W Sherman Horizon Therapeutics Public LTD CO (HZNP) insider trading activity

Jeffrey W Sherman is EVP and Chief Medical Officer of Horizon Therapeutics Public Ltd Co. Currently has a direct ownership of 0 shares of HZNP, which is worth approximately $0. The most recent transaction as insider was on Oct 06, 2023, when has been sold 2,655 shares (Ordinary Shares) at a price of $116.5 per share, resulting in proceeds of $309,307. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

JEFFREY W SHERMAN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 06 2023	SELL Sale (or disposition) back to the issuer	$309,307 $116.5 p/Share	2,655 Reduced 100.0%	0 Ordinary Shares
Jan 17 2023	SELL Bona fide gift	-	33,795 Reduced 93.43%	2,376 Ordinary Shares
Jan 11 2023	SELL Open market or private sale	$380,920 $113.1 p/Share	3,368 Reduced 8.52%	36,171 Ordinary Shares
Jan 10 2023	SELL Open market or private sale	$380,752 $113.05 p/Share	3,368 Reduced 7.85%	39,539 Ordinary Shares
Jan 05 2023	SELL Payment of exercise price or tax liability	$2,565,452 $113.24 p/Share	22,655 Reduced 34.56%	42,907 Ordinary Shares
Jan 05 2023	BUY Exercise of conversion of derivative security	-	51,132 Added 43.82%	65,562 Ordinary Shares
Jan 01 2023	SELL Payment of exercise price or tax liability	$1,105,794 $113.8 p/Share	9,717 Reduced 40.24%	14,430 Ordinary Shares
Jan 01 2023	BUY Exercise of conversion of derivative security	-	21,772 Added 47.41%	24,147 Ordinary Shares
May 27 2022	SELL Bona fide gift	-	8,531 Reduced 78.22%	2,375 Ordinary Shares
Apr 06 2022	SELL Open market or private sale	$4,621,830 $110.02 p/Share	42,009 Reduced 79.81%	10,629 Ordinary Shares
Mar 18 2022	BUY Exercise of conversion of derivative security	$188,876 $22.14 p/Share	8,531 Added 13.95%	52,638 Ordinary Shares
Mar 10 2022	SELL Bona fide gift	-	8,169 Reduced 15.63%	44,107 Ordinary Shares
Jan 21 2022	SELL Payment of exercise price or tax liability	$204,988 $86.42 p/Share	2,372 Reduced 3.85%	59,293 Ordinary Shares
Jan 21 2022	BUY Exercise of conversion of derivative security	-	5,354 Added 7.99%	61,665 Ordinary Shares
Jan 05 2022	SELL Payment of exercise price or tax liability	-	37,675 Reduced 40.09%	56,311 Ordinary Shares
Jan 05 2022	BUY Grant, award, or other acquisition	-	32,301 Added 25.58%	93,986 Ordinary Shares
Jan 05 2022	BUY Exercise of conversion of derivative security	-	52,570 Added 46.01%	61,685 Ordinary Shares
Nov 08 2021	SELL Bona fide gift	-	10,729 Reduced 54.07%	9,115 Ordinary Shares
Oct 27 2021	BUY Exercise of conversion of derivative security	$81,648 $7.61 p/Share	10,729 Added 35.09%	19,844 Ordinary Shares
Sep 21 2021	SELL Open market or private sale	$5,089,810 $110.0 p/Share	46,271 Reduced 83.54%	9,115 Ordinary Shares
Sep 21 2021	BUY Exercise of conversion of derivative security	$352,122 $7.61 p/Share	46,271 Added 45.52%	55,386 Ordinary Shares
Sep 03 2021	SELL Bona fide gift	-	4,042 Reduced 30.72%	9,115 Ordinary Shares
Jul 28 2021	SELL Payment of exercise price or tax liability	$329,538 $102.5 p/Share	3,215 Reduced 19.64%	13,157 Ordinary Shares
Jul 28 2021	BUY Grant, award, or other acquisition	-	7,257 Added 30.71%	16,372 Ordinary Shares
Jul 01 2021	SELL Open market or private sale	$502,265 $95.0 p/Share	5,287 Reduced 36.71%	9,115 Ordinary Shares

Also insider at

SBBP

Strongbridge Biopharma plc

Director

XERS

XERIS PHARMACEUTICALS INC Healthcare

Director

XERS

Xeris Biopharma Holdings, Inc. Healthcare

Director

LRMR

Larimar Therapeutics, Inc. Healthcare

Director

JWS